PubRank

Gunvant K Thaker

Author PubWeight™ 57.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008 2.05
2 Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. Arch Gen Psychiatry 2009 2.03
3 Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry 2008 1.78
4 Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry 2013 1.76
5 A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci U S A 2010 1.70
6 Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res 2004 1.65
7 Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 2009 1.41
8 Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am J Psychiatry 2013 1.35
9 Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2011 1.33
10 Genetics and intermediate phenotypes of the schizophrenia--bipolar disorder boundary. Neurosci Biobehav Rev 2009 1.26
11 Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011 1.22
12 Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003 1.18
13 Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry 2007 1.06
14 Specific motion processing pathway deficit during eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study. Biol Psychiatry 2005 1.04
15 Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport 2004 1.04
16 Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) 2004 1.03
17 Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval. Am J Psychiatry 2007 1.02
18 Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord 2007 1.00
19 Components of the smooth pursuit function in deficit and nondeficit schizophrenia. Schizophr Res 2003 0.99
20 Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003 0.99
21 Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans. Psychophysiology 2007 0.99
22 Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch Gen Psychiatry 2006 0.98
23 Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull 2006 0.97
24 A shared low-frequency oscillatory rhythm abnormality in resting and sensory gating in schizophrenia. Clin Neurophysiol 2011 0.97
25 Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry 2002 0.96
26 Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. Schizophr Bull 2013 0.94
27 The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 2002 0.94
28 Refining the predictive pursuit endophenotype in schizophrenia. Biol Psychiatry 2007 0.93
29 Is motion perception deficit in schizophrenia a consequence of eye-tracking abnormality? Biol Psychiatry 2008 0.91
30 Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology 2007 0.91
31 Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2009 0.90
32 Association between polymorphism of the SNAP29 gene promoter region and schizophrenia. Schizophr Res 2005 0.89
33 Role of anticipation in schizophrenia-related pursuit initiation deficits. J Neurophysiol 2005 0.89
34 Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull 2009 0.89
35 Are structural brain abnormalities associated with suicidal behavior in patients with psychotic disorders? J Psychiatr Res 2013 0.87
36 Cognitive endophenotypes of psychosis within dimension and diagnosis. Psychiatry Res 2012 0.87
37 Smooth pursuit eye movement, prepulse inhibition, and auditory paired stimuli processing endophenotypes across the schizophrenia-bipolar disorder psychosis dimension. Schizophr Bull 2013 0.86
38 Response to unexpected target changes during sustained visual tracking in schizophrenic patients. Exp Brain Res 2005 0.85
39 Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2005 0.83
40 Reliability of a portable head-mounted eye tracking instrument for schizophrenia research. Behav Res Methods 2005 0.81
41 Neurophysiological markers of vulnerability to schizophrenia: sensitivity and specificity of specific quantitative eye movement measures. J Abnorm Psychol 2002 0.81
42 Neurodevelopmental interactions conferring risk for schizophrenia: a study of dermatoglyphic markers in patients and relatives. Schizophr Bull 2003 0.80
43 Deficits on the Continuous Performance Test within the schizophrenia spectrum and the mediating effects of family history of schizophrenia. J Abnorm Psychol 2006 0.80
44 Boundaries of the psychosis phenotype. Schizophr Bull 2012 0.79
45 Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct 2006 0.79
46 Current progress in schizophrenia research. Eye movement abnormalities in schizophrenia: what is the nature of the deficit? J Nerv Ment Dis 2002 0.79
47 Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 2004 0.79
48 Predictive pursuit association with deficits in working memory in psychosis. Biol Psychiatry 2012 0.78
49 Endophenotypic studies in schizophrenia: promise and challenges. Schizophr Bull 2006 0.78
50 Family history of psychosis moderates early auditory cortical response abnormalities in non-psychotic bipolar disorder. Bipolar Disord 2013 0.78
51 Effects of repeated amphetamine administration on antisaccade in schizophrenia spectrum personality. Psychiatry Res 2006 0.78
52 Evidence-based therapeutics--introducing the Cochrane corner. Schizophr Bull 2007 0.77
53 Naltrexone treatment of tardive dyskinesia in patients with schizophrenia. J Clin Psychopharmacol 2004 0.77
54 Current progress in schizophrenia research: cognitive phenotypes of schizophrenia: attention. J Nerv Ment Dis 2002 0.77
55 Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype. Schizophr Bull 2003 0.77
56 Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmacology (Berl) 2011 0.76
57 Psychopathological and cognitive correlates of tardive dyskinesia in patients treated with neuroleptics. Adv Neurol 2005 0.76
58 Schizophrenia, VII: defining the neurobiology of risk factors. Am J Psychiatry 2003 0.75
59 Schizophrenia, V: risk markers. Am J Psychiatry 2003 0.75